This page collects WhisperX intelligence signals tagged #创新药转型. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The annual profit card of 2025 million yuan was issued on the evening of 16 March, and the company achieved business income of 2,158 million yuan a year, an increase of 8.93 per cent; however, the net profit earned by the mother amounted to $241 million, resulting in a net loss of $294 million. This is the first annual...
石药集团交出了一份令市场错愕的2025年成绩单。全年营收260.06亿元，同比下滑10.4%；净利润38.82亿元，同比下降10.3%。在行业普遍兑现商业化的背景下，这家头部药企成为少数营收下滑的公司，其两年前“超越恒瑞医药”的市场预期彻底落空，转型的阵痛在核心财务数据上暴露无遗。 阵痛根源在于历史路径依赖与政策冲击的叠加。石药集团曾将资源高度倾斜于销售端，其2018年“销研比”高达4.6:1，远超同期恒瑞医药的2.4:1。这一策略在仿制药红利时代支撑了恩必普、津优力、多美素等大单品的放量。然而，随着国家集采与医保谈判政策落地，仿制药价格体系崩塌，后遗症集中爆发。2025年，核心产品恩必普因医保谈判降价导致收入下滑；抗肿瘤药物多美...